search
Back to results

Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery

Primary Purpose

Cardiovascular Surgery, Pain, Postoperative, Block

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Liposomal bupivacaine
Normal Saline Flush, 0.9% Injectable Solution_#1
Sponsored by
Baylor Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Cardiovascular Surgery

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age greater than 18 years
  2. Undergoing a surgical procedure through mini- or full sternotomy.

Exclusion Criteria:

  1. Clinical instability
  2. Allergic to liposomal bupivacaine solution or any of its ingredients
  3. Maximum-allowed dosage of local analgesia will be exceeded by the injection amount of liposomal bupivacaine used in this study (<50 kg).
  4. BMI >45
  5. Pregnant or nursing
  6. Chronic home opioid usage
  7. Left Ventricular Ejection Fraction (LVEF) < 30%
  8. Low cardiac output requiring mechanical or inotropic support
  9. End-stage renal disease
  10. Cirrhosis

Sites / Locations

  • Baylor Scott & White Heart Hospital - PlanoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Liposomal Bupivacaine Block

Saline Block

Arm Description

Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.

Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.

Outcomes

Primary Outcome Measures

Postoperative opioid measured in Milligram Morphine Equivalent (MME)
The amount of opioid medications used will be recorded during the routine postoperative course.
Postoperative Pain Scores measured with standard pain scores (0-10)
Range 0 (No pain) to 10 (Worst pain)

Secondary Outcome Measures

Intraoperative opioid usage measured in Milligram Morphine Equivalent (MME)

Full Information

First Posted
March 27, 2020
Last Updated
June 8, 2021
Sponsor
Baylor Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04333095
Brief Title
Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery
Official Title
Regional Blockade of the Sternum With Liposomal Bupivacaine Prior to Incision Decreases Opioid Use in Patients Undergoing Cardiac Surgery (Sternal Block)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Recruiting
Study Start Date
February 6, 2020 (Actual)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
June 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Baylor Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to find out what effects (good and bad) that the study medicine called "liposomal bupivacaine" has on subjects that are undergoing a sternotomy. Liposomal bupivacaine solution, is a drug that the doctor will inject before they make the cut through patient's breastbone (sternotomy). Normally pain medicine like this is given right before the surgeon closes up the patient's breastbone, at the end of the surgery. For this study, they want to see if giving the medicine before they make the cut into the patient's breastbone helps their pain. They also want to find out if patients feel less pain after surgery with the study drug than they do with saline and possibly decrease the need for pain medicine. Subjects will be in the study for about 72 hours or until they are discharged from the hospital.
Detailed Description
Background: Prolonged and excessive narcotic usage in the postoperative setting has been linked to multiple complications. Use of complimentary pain management techniques such as regional analgesia can reduce postoperative pain and narcotic usage. This can enhance patient recovery and improve quality of life in the immediate postoperative period. Previous research investigating the benefits of local analgesia during cardiac surgery have been limited by the sparse amount of single-center randomized controlled trials, particularly evaluating the use of para-sternal injections. Of the available studies, the use of local analgesia injections compared to controls has led to improved pain scores and overall decreased perioperative opioid usage. Studies have shown this efficacy using 0.2% ropivacaine, 0.75% ropivacaine, and 0.53% liposomal bupivacaine all compared to control groups receiving normal saline injections in the para-sternal area. These studies all used injections just prior to sternal closure and no significant evidence is available for the use of ultrasound-guided regional block of the sternum prior to surgical incision. Injection of analgesia prior to surgical incision has been shown to decrease postoperative pain compared to injection after surgical closure. We hypothesize that injection of 1.3% liposomal bupivacaine and 0.5% bupivacaine (20mL dose) as a sternal block prior to surgical incision will lead to decreased pain and opioid usage in the intraoperative and postoperative setting for patients undergoing upper mini- and median sternotomy compared to controls. Methods: This is an investigator-initiated prospective randomized study with an 18-month patient accrual period and patient follow-up period dependent on postoperative length of stay following surgery. Regional Block: Liposomal Bupivacaine (1.3%) solution (20 mL dose) is proposed for use during this study. This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block. Normal Saline: Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution. Procedures: Patients undergoing a surgical procedure through mini- or full sternotomy will be considered for inclusion in this study. There will be no deviation from routine surgical procedures following injection of para-sternal solution prior to surgical incision. Data elements: Patient Characteristics: Age Gender BMI Tobacco use Chronic lung disease Diabetes Hypertension (HTN) Hyperlipidemia (HLD) Ethnicity (Hispanic & not Hispanic) Race (Caucasian, African Americans, Asians and others) Chronic Kidney Disease (CKD) Cerebrovascular accident (CVA) Chronic home non-steroidal anti-inflammatory drug (NSAID) use (excluding acetylsalicylic acid (ASA)) Intraoperative Variables: Type of procedure being performed Prior procedures performed Postoperative Variables: Time to extubation, time to ambulation, time to oral diet, return of bowel function, postoperative atrial fibrillation incidence, post op nausea incidence, and intensive care unit (ICU) length of stay (LOS) and overall LOS. Maximum incentive spirometer maximum volume at 24, 48 and 72 hours, Confusion assessment method (CAM) at 24, 48 and 72 hours, post op opioid usage up to 72 hours post op. If additional days of post-op opioid usage is documented in the existing medical record, this may be used also. Pain scores (Scale 0-10) at 1, 2, 4, 8, 12,24,36,48, 60, and 72 hours after ICU arrival for extubated patients and Clinical Care Pain Observation Tool (CPOT)scores (Scale 0-8) for intubated patients Adverse Events: Allergic reaction, pneumothorax, pericardial tamponade, vascular injury, hematoma, intravascular injection, wound infection, paresthesia, persistent numbness Protocol Deviations: If certain data elements are not in the existing medical record and were not collected, this is not a protocol deviation. Nevertheless, all effort will be made to collect these data points. Risks and Benefits Risks: The risks are the same as the Standard of Care surgery performed outside this study. This is discussed in the ICF. A confidentiality breach is a risk associated with research. However, all data collection protocols follow HIPAA guidance. Benefits: If participants receive the drug, they could experience less pain than those that don't receive the drug. However, not all participants are likely to benefit from the proposed research. The investigators will benefit from the knowledge gained, as it will provide deepened insight on the main challenges, advantages and disadvantages of the procedure. Data Analytic Methods The mean, standard deviation, median, and interquartile ranges of narcotic usage (in morphine equivalent units) will be reported for each group. The difference of narcotic usage between the two groups will be reported as a single value. Additional variables analyzed in this study include the following: Patient Characteristics: Age Gender BMI Tobacco use Chronic pain medication usage Diabetes HTN HLD Race & Ethnicity CKD CVA Intraoperative Variables: Type of procedure being performed Prior procedures performed Postoperative Variables: Time to extubation Time to ambulation Time to oral diet Postoperative nausea ICU LOS Total LOS Return of bowel function Postoperative atrial fibrillation Maximum spirometry at 24, 48, 72 hours post op CAM at 24, 48, 72 hours post op Pain Scores (Scale 0-10) at 1, 2, 4, 8, 12,24,36,48, 60, and 72 hours after ICU arrival for extubated patients and CPOT scores (Scale 0-8) for intubated patients Post op opioid usage up to 72 hours post op Standard descriptive statistics will be used throughout (mean, range, standard deviation, and median, IQR), with comparative statistics for normally and non-normally distributed data with p<0.05 considered as significant. For categorical variables, 2 Sample t-test or chi-squared test will be used to determine statistical significance. For continuous variables, logistic regression will be used to determine the value of significance to variables with postoperative outcomes. Depending on the enrollment rate, the stratification of data based on the type of sternotomy (full or mini) could be performed and analyzed respectively.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Surgery, Pain, Postoperative, Block

7. Study Design

Primary Purpose
Other
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The surgeon, coordinator and anesthesiologist on the case are blinded to the block drug. A 2nd (unblinded) anesthesiologist performs the block on the patient.
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Liposomal Bupivacaine Block
Arm Type
Active Comparator
Arm Description
Liposomal Bupivacaine (1.3%) solution (20 mL dose). This solution has demonstrated increased efficacy in prolonged analgesia following injection. This solution will be injected as an ultrasound-guided subpectoral interfacial plane block.
Arm Title
Saline Block
Arm Type
Placebo Comparator
Arm Description
Normal saline (0.9%) will be used as the control solution for patients not receiving the liposomal bupivacaine solution. Injection procedure of this solution will be identical to that of the liposomal bupivacaine solution.
Intervention Type
Drug
Intervention Name(s)
Liposomal bupivacaine
Intervention Description
Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
Intervention Type
Drug
Intervention Name(s)
Normal Saline Flush, 0.9% Injectable Solution_#1
Intervention Description
Sternal Block during Coronary Artery Bypass Graft Surgery and/or surgical aortic valve replacement through mini- or full sternotomy
Primary Outcome Measure Information:
Title
Postoperative opioid measured in Milligram Morphine Equivalent (MME)
Description
The amount of opioid medications used will be recorded during the routine postoperative course.
Time Frame
Up to 72 hours post-op
Title
Postoperative Pain Scores measured with standard pain scores (0-10)
Description
Range 0 (No pain) to 10 (Worst pain)
Time Frame
Up to 72 hours post-op
Secondary Outcome Measure Information:
Title
Intraoperative opioid usage measured in Milligram Morphine Equivalent (MME)
Time Frame
During surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age greater than 18 years Undergoing a surgical procedure through mini- or full sternotomy. Exclusion Criteria: Clinical instability Allergic to liposomal bupivacaine solution or any of its ingredients Maximum-allowed dosage of local analgesia will be exceeded by the injection amount of liposomal bupivacaine used in this study (<50 kg). BMI >45 Pregnant or nursing Chronic home opioid usage Left Ventricular Ejection Fraction (LVEF) < 30% Low cardiac output requiring mechanical or inotropic support End-stage renal disease Cirrhosis
Facility Information:
Facility Name
Baylor Scott & White Heart Hospital - Plano
City
Plano
State/Province
Texas
ZIP/Postal Code
75093
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sarah M Hale, BA
Phone
469-814-4720
Email
sarah.hale@bswhealth.org
First Name & Middle Initial & Last Name & Degree
Katherine B Harrington, MD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
At this point, we do not plan to shared IPD but will share cumulative results in an abstract and manuscript.
Citations:
PubMed Identifier
29027773
Citation
Bignami E, Castella A, Pota V, Saglietti F, Scognamiglio A, Trumello C, Pace MC, Allegri M. Perioperative pain management in cardiac surgery: a systematic review. Minerva Anestesiol. 2018 Apr;84(4):488-503. doi: 10.23736/S0375-9393.17.12142-5. Epub 2017 Oct 12.
Results Reference
background
PubMed Identifier
14665996
Citation
Dowling R, Thielmeier K, Ghaly A, Barber D, Boice T, Dine A. Improved pain control after cardiac surgery: results of a randomized, double-blind, clinical trial. J Thorac Cardiovasc Surg. 2003 Nov;126(5):1271-8. doi: 10.1016/s0022-5223(03)00585-3.
Results Reference
background
PubMed Identifier
17678782
Citation
Barr AM, Tutungi E, Almeida AA. Parasternal intercostal block with ropivacaine for pain management after cardiac surgery: a double-blind, randomized, controlled trial. J Cardiothorac Vasc Anesth. 2007 Aug;21(4):547-53. doi: 10.1053/j.jvca.2006.09.003. Epub 2006 Dec 22.
Results Reference
background
PubMed Identifier
30170012
Citation
Lee CY, Robinson DA, Johnson CA Jr, Zhang Y, Wong J, Joshi DJ, Wu TT, Knight PA. A Randomized Controlled Trial of Liposomal Bupivacaine Parasternal Intercostal Block for Sternotomy. Ann Thorac Surg. 2019 Jan;107(1):128-134. doi: 10.1016/j.athoracsur.2018.06.081. Epub 2018 Aug 28.
Results Reference
background
PubMed Identifier
28867907
Citation
Labrum JT 4th, Ilyas AM. Preemptive Analgesia in Thumb Basal Joint Arthroplasty: Immediate Postoperative Pain with Preincision versus Postincision Local Anesthesia. J Hand Microsurg. 2017 Aug;9(2):80-83. doi: 10.1055/s-0037-1603734. Epub 2017 Jun 5.
Results Reference
background

Learn more about this trial

Sternal Block With Liposomal Bupivacaine vs. Saline Prior to Incision in Cardiac Surgery

We'll reach out to this number within 24 hrs